Sign in Subscribe
Diseases

Alzheimer's Disease Market Set to Expand with Emerging Therapies

Strategic Insights

— 2 min read

Alzheimer's disease is a chronic and progressive neurological condition that affects memory, thinking, and other cognitive functions, with approximately 60-80% of dementia cases attributed to it. The disease is strongly linked to the buildup of amyloid beta plaques and tau tangles in the brain, which interfere with neural communication and trigger brain cell death. With a significant impact on public health systems, Alzheimer's disease poses an urgent need for innovative treatment approaches.

DelveInsight analysts project that Alzheimer's cases will continue to rise over the coming years, with a substantial increase in diagnosed prevalent cases across the 7MM. In the United States, nearly 2.4 million men and 5 million women were diagnosed with Alzheimer's in 2024, with numbers expected to increase by 2034. The 75-84 age group recorded the highest prevalence of Alzheimer's in the EU4 and the UK in 2024, with around 2 million cases, while individuals under 65 accounted for the lowest prevalence, with approximately 130,000 cases.

Key Takeaways:

  • DelveInsight estimates that 2.4 million males and 5 million females were affected with Alzheimer's disease in the US in 2024.
  • The numbers are expected to increase by 2034, highlighting the growing healthcare burden Alzheimer's poses in the U.S.
  • Key companies such as Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Suven Life Sciences, and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
  • Alzheimer's disease affected around 16 million diagnosed individuals across the 7MM in 2024, with Germany reporting the highest number of diagnosed prevalent cases.
  • The 75-84 age group recorded the highest prevalence of Alzheimer's in the EU4 and the UK in 2024, with around 2 million cases.
  • In Japan, there were an estimated 2.5 million diagnosed cases of agitation related to Alzheimer's disease in 2024, a behavioral complication characterized by restlessness, aggression, anxiety, and irritability.

Statistics:

  • 2.4 million males and 5 million females were affected with Alzheimer's disease in the US in 2024.
  • Alzheimer's cases will increase by 2034, highlighting the growing healthcare burden Alzheimer's poses in the U.S.
  • 16 million diagnosed individuals across the 7MM were affected with Alzheimer's disease in 2024.
  • 2 million cases of Alzheimer's disease were reported in the 75-84 age group in the EU4 and the UK in 2024.
  • 2.5 million diagnosed cases of agitation related to Alzheimer's disease were reported in Japan in 2024.

Sources:

  • DelveInsight analysis
  • M2 PressWIRE - October 17, 2025
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk))

Read more